$3.11
+2.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.18
From 52W high−58.53%
Volume33086.00
Market cap$4.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.18
From 52W high
−58.53%
Volume
33086.00
Market cap
$4.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
37.2
MomentumView details →
1D Return
+2.30%
YTD Return
+408.20%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMN) is a clinical-stage biotechnology company founded and based in La Palma, California. The company went public in May 2025, representing a relatively new entrant to the public markets in the immuno-oncology space. As a clinical-stage company, Liminatus is focused on developing novel cancer therapies that harness the body's immune system to fight cancer, though the company is still in early stages of development with no current revenue generation.
Similar companies
Latest newsMore news →
Liminatus Pharma regained compliance with Nasdaq's $1 minimum bid price requirement after effecting a 1-for-50 reverse stock split on August 20, 2026.21d agoLiminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.62d agoLiminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.63d ago